Global RNAi Drug Delivery Market 2014-2018

Global RNAi Drug Delivery Market 2014-2018

Category : Diagnostic and Biotech
Published On : January  2014
Pages : 45



TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

TechNavio's analysts forecast the Global RNAi Drug Delivery market to grow at a CAGR of 21.80 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in RNA therapeutic development. The Global RNAi Drug Delivery market has also been witnessing some key technological advancements. However, the targeted delivery of RNA molecules is expected to pose a challenge to the growth of this market. 
TechNavio's report, the Global RNAi Drug Delivery Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global RNAi Drug Delivery market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this space are Alnylam Pharmaceuticals Inc., Isis Pharmaceuticals, Inc.,Merck & Co. Inc., and Tekmira Pharmaceuticals Corp..
Other vendors mentioned in the report are Access Pharmaceuticals Inc., Calondo Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Marina Biotech Inc., PhaseRx Inc., Quark Pharmaceuticals Inc., RXi Pharmaceuticals Corp., Silence Therapeutics plc, Sirnaomics Inc., Tacere Therapeutics Inc., and Traversa Therapeutics Inc.
Key questions answered in this report: 
What will the market size be in 2018 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

 

 

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report


03.1 Market Overview

03.2 Technology Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape


06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Market Segmentation

07.1 Overview

08. Geographical Segmentation

09. Buying Criteria

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Trends and their Impact

16. Vendor Landscape


16.1 Competitive Scenario

16.1.1 Key News

16.1.2 Prominent Vendors

17. Key Vendor Analysis

17.1 Alnylam Pharmaceuticals Inc.

17.1.1 Business Overview

17.1.2 Key Information

17.1.3 SWOT Analysis

17.2 Isis Pharmaceuticals Inc.

17.2.1 Business Overview

17.2.2 Key Information

17.2.3 SWOT Analysis

17.3 Merck & Co. Inc.

17.3.1 Business Overview

17.3.2 Business Segmentation

17.3.3 Key Information

17.3.4 SWOT Analysis

17.4 Tekimira Pharmaceuticals Corp.

17.4.1 Business Overview

17.4.2 Key Information

17.4.3 SWOT Analysis

18. Other Reports in this Series



List of Exhibits

Exhibit 1: Market Research Methodology

Exhibit 2: Global RNAi Drug Delivery Market 2013-2018 (US$ billion)

Exhibit 3: Global RNAi Drug delivery market-Segmentation by Types

Exhibit 4: Global RNAi drug delivery Market By Types 2013

Exhibit 5: Global RNAi Drug Delivery Market By Geography 2013

Exhibit 6: Business Segmentation of Merck& Co. Inc.


 


Enquiry Before Buy
image
Can´t read the image ? refresh here.